Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 5, 2009, Pages 2014-2019

  Hughes, Darrel W ^a,b,c   Frei, Christopher R ^b,c   Maxwell, Pamela R ^a,b,c   Green, Kay ^a   Patterson, Jan E ^c,d   Crawford, George E ^c,d   Lewis II, James S ^a,b,c  

^a UNIVERSITY HEALTH SYSTEM   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; GENTAMICIN; OXACILLIN; VANCOMYCIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTEREMIA; BACTERIAL ENDOCARDITIS; CONTINUOUS INFUSION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; ENDOCARDITIS, BACTERIAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHICILLIN; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OXACILLIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 66149133616     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01232-08     Document Type: Article

References (23)

1. Baddour, L. M., W. R. Wilson, A. S. Bayer, V. G. Fowler, Jr., A. F. Bolger, M. E. Levison, P. Ferrieri, M. A. Gerber, L. Y. Tani, M. H. Gewitz, D. C. Tong, J. M. Steckelberg, R. S. Baltimore, S. T. Shulman, J. C. Burns, D. A. Falace, J. W. Newburger, T. J. Pallasch, M. Takahashi, and K. A. Taubert. 2005. Infective endocarditis: diagnosis, antimicrobial therapy and management of complications. Circulation 111:e394-e434.
2. Bayer, A. S., A. F. Bolger, K. A. Taubert, W. Wilson, J. Stekelberg, A. W. Karchmer, M. Levison, H. F. Chambers, A. S. Dajani, M. H. Gewitz, J. W. Newburger, M. A. Gerber, S. T. Shluman, T. J. Pallasch, T. W. Gage, and P. Ferrieri. 1998. Diagnosis and management of infective endocarditis and its complications. Circulation 98:2936-2948. (Pubitemid 29003982)
3. Betts, R. F., S. W. Chapman, and R. L. Penn (ed.). 2002. A practical approach to infectious disease, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
4. Cabell, C. H., J. G. Jollis, G. E. Peterson, G. R. Corey, D. J. Anderson, D. J. Sexton, C. W. Woods, B. Reller, T. Ryan, and V. G. Fowler, Jr. 2002. Changing patient characteristics and the effect on mortality in endocarditis. Arch. Intern. Med. 162:90-94.
5. Craig, W. A., and S. C. Ebert. 1992. Continuous infusion of β-lactam antibiotics. Antimicrob. Agents Chemother. 36:2577-2583.
6. Durack, D. T., A. S. Lukes, and D. K. Bright. 1994. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Am. J. Med. 96:200-209. (Pubitemid 24099217)
7. Florea, N. R., S. Kotapati, J. L. Kuti, E. C. Ceissler, C. H. Nightingale, and D. P. Nicolau. 2003. Cost analysis of continuous versus intermittent infusion of pipercillin-tazobactam: a time-motion study. Am. J. Health Syst. Pharm. 60:2321-2327.
8. Fowler, V. G., Jr., H. W. Boucher, R. Corey, E. Abrutyn, A. W. Karchmer, M. E. Rupp, D. P. Levine, H. F. Chambers, F. P. Rally, G. A. Vigliani, C. H. Cabell, A. S. Link, I. DeMeyer, S. G. Filler, M. Zervos, P. Cook, J. Parsonnet, J. M. Bernstein, C. S. Price, G. N. Forrest, G. Fatkenheuer, M. Gareca, S. J. Rehm, H. R. Brodt, A. Tice, and S. E. Cosgrove. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
9. Fowler, V. G., Jr., J. M. Miro, B. Hoen, C. H. Cabell, E. Abrutyn, E. Rubinstein, G. R. Corey, D. Spelman, S. F. Bradley, B. Barsic, P. A. Pappas, K. J. Anstrom, D. Wray, C. Q. Fortes, I. Anguera, E. Athan, P. Jones, J. T. M. van der Meer, T. S. J. Elliott, D. P. Levine, and A. S. Bayer. 2005. Staphylococcus aureus endocarditis throughout the world: a consequence of medical progress. JAMA 293:3012-3021.
10. Hardman, J. G., L. E. Limbird, and A. G. Gilman (ed.). 2001. Goodman & Gilman's the pharmacological basis of therapeutics, 10th ed. McGraw-Hill, New York, NY.
11. Hoen, B., F. Alla, C. Selton-Suty, I. Beguinot, A. Bouvet, S. Briancon, J. P. Casalta, N. Danchin, F. Delahaye, J. Etienne, V. Le Moing, C. Leport, J. L. Mainardi, R. Ruimy, and F. Vandenesch. 2002. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA 288:75-81. (Pubitemid 34705521)
12. Kalso, R. K. (ed.). 3 February 2009, accession date. Drugdex system (electronic version). Thomson Micromedex, Greenwood Village, CO.
13. Korzeniowski, O., and M. A. Sande. 1982. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parental drugs and in nonaddicts: a prospective study. Ann. Intern. Med. 97:496-503.
14. Li, J. S., D. J. Sexton, N. Mick, R. Nettles, V. G. Fowler, Jr., T. Ryan, T. Bashore, and G. R. Corey. 2000. Proposed modifications to the Duke criteria for the diagnosis infective endocarditis. Clin. Infect. Dis. 30:633-638.
15. Miro, J. M., I. Anguera, C. H. Cabell, A. Y. Chen, J. A. Stafford, G. R. Corey, L. Olaison, S. Eykyn, B. Hoen, E. Abrutyn, D. Raoult, A. Bayer, and V. G. Fowler, Jr. 2005. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin. Infect. Dis. 41:507-514.
16. Mourvillier, B., J. L. Trouillet, J. F. Timsit, J. Baudot, J. Chastre, B. Regnier, C. Gibert, and M. Wolff. 2004. Infective endocarditis in the intensive care unit: clinical spectrum and prognostic factors in 228 consecutive patients. Intensive Care Med. 30:2046-2052. (Pubitemid 40022320)
17. Mylonakis, E., and S. B. Calderwood. 2001. Infective endocarditis in adults. N. Engl. J. Med. 345:1318-1330.
18. Pannu, N., and M. K. Nadim. 2008. An overview of drug-induced acute kidney injury. Crit. Care Med. 36:S216-S223.
19. PMIC. 2008. ICD-9-CM: international classification of diseases, 9th revision; clinical modification, 6th ed, vol.1, 2, 3. Practice Management Information Corporation, Los Angeles, CA.
20. Remadi, J. P., G. Habib, G. Nadji, A. Brahim, F. Thuny, J. P. Casalta, M. Peltier, and C. Tribouilloy. 2007. Predictors of death and impact of surgery in Staphylococcus aureus infective endocarditis. Ann. Thorac. Surg. 83:1295-1302.
21. Ruotsalainen, E., K. Sammalkorpi, J. Laine, K. Huotari, S. Sarna, V. Valtonen, and A. Jarvinen. 2006. Clinical manifestations and outcome in Staphylococcus aureus endocarditis among injection drug users and nonaddicts: a prospective study of 74 patients. BMC Infect. Dis. 6:137-147.
22. Rybak, M. J., B. J. Abate, S. L. Kang, M. J. Ruffing, S. A. Lerner, and G. L. Drusano. 1999. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob. Agents Chemother. 43:1549-1555. (Pubitemid 29331226)
23. Turnidge, J. D. 1998. The pharmacodynamics of β-lactams. Clin. Infect. Dis. 27:10-22. (Pubitemid 28334412)